On: ‘Life saving’ drug for people with opioid dependency to be pulled from Australia

July 2, 2026.

I read the dispatch from the Antipodes. A pharmaceutical firm, Camurus, has announced the withdrawal of Buvidal from the Australian market by the end of the year. The reason provided by the industry observers is a “strategic recalibration of global supply chains in response to shifting regulatory environments.”

“Strategic recalibration.” Note the nominalization. The verb “to abandon” or “to kill” has been processed into a noun of four syllables. A recalibration is a technical adjustment, like the tuning of a piano or the setting of a watch. It suggests a movement toward precision, when in fact it describes the removal of a chemical lifeline from thousands of human bodies. The grammar does not permit a subject; the “environment” shifts, and the “recalibration” follows. No one is withdrawing the drug; the market is simply “reacting.”

In the same breath, the report mentions: “Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administration.”

Observe the “react.” It is the favorite verb of the coward. It transforms a deliberate choice of the boardroom into a biological reflex. If a man strikes another, he “acts.” If a corporation denies a terminal patient their medicine to protect a margin in a distant capital, it “reacts.” The policy change is the stimulus; the withdrawal is the involuntary twitch.

The “life-saving” quality of the drug is placed in quotation marks by the editors, as if to distance the paper from the physical reality of the withdrawal. The marks function as a prophylactic against the truth. By the end of the year, the grammar will be perfect, the recalibration will be complete, and the bodies will be silent. The sentence survives the patient.